Expanding medical diagnostics for low-and-middle income countries: GADx, UK

Global Access Diagnostics (GADx), formerly known as Mologic, was formed in 2003 and is a UK-based social enterprise that aims to expand access to medical technologies in low-and-middle-income country settings. 

GADx has a broad portfolio of rapid diagnostics, with 10 innovative products for epidemics and neglected diseases. UTRiPLEX is GADx’s rapid point-of-care UTI pathogen detection test. UTRiPLEX is a single lateral flow strip that uses biomarkers to produce a qualitative or semi-quantitative result within 6 minutes. 

“Being part of the Longitude Prize on AMR has enabled us to put our best teams, our focus, and our energy on our AMR portfolio because we believe this is going to be extremely impactful. We hope that the example that GADX sets has become a social enterprise will enable other innovators to join us on that journey in order that all tests are more accessible in our settings where they’re so crucial.” Dr Emily Adams

Co-founder and Chief Scientific Officer, Paul Davis, was the originator of the Clearblue pregnancy test, the world’s first commercial application of lateral flow technology. 

The creativity, insight and knowledge that led to that groundbreaking invention has guided GADx since its formation, and GADx has been behind some of the most important innovations in rapid point-of-care diagnosis since.

Speakers in this video from the GADx team:

Dr Emily Adams, Director of Epidemics and Neglected Tropical Diseases, GADx

Devanshi Pandit, Clinical Trials Manager, GADx